Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by CADInvestor12on Oct 29, 2024 1:48pm
146 Views
Post# 36287166

MPL Q3 & Onward

MPL Q3 & OnwardFingers crossed that Q3 earnings continue to build off Q1 & Q2 momentum ... would be nice if they comment on US rescheduling, at a high level rescheduling will allow them to compete in US market (Dronabinol/ Sativex/ Marinol all currently derived synthetically) + who knows what other opps they are working on ... wish this came from management but it looks like the Brazil partner (or 1 of) is Active Pharmaceutca Ltd, acquired by Caldic .. can't find much info on them ... see on page 6 of link below:

https://www.gov.br/anvisa/pt-br/composicao/diretoria-colegiada/reunioes-da-diretoria/extratos-dos-circuitos-deliberativos-1/2023/extrato-cd-1003-2023-2013-cronograma-de-inspecao-25351-9271762023-56.pdf/@@download/file
<< Previous
Bullboard Posts
Next >>